Centessa Pharmaceuticals plc (CNTA)
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients.
Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.
The company also develops LB101, a PD-L1xCD47 LockBody, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874 in alpha-1 antitrypsin deficiency, a dual-STAT3/5 degrader program in acute myeloid leukemia (AML); MGX292, a protein-engineered variant of human bone morphogenetic protein 9 (BMP9) for the treatment of pulmonary arterial hypertension (PAH); and OX2R Agonists compounds are currently in development for the treatment of narcolepsy, including TAK-861.
In addition, its products pipeline comprises CBS001, a neutralizing therapeutic mAb to the inflammatory membrane form of LIGHT for inflammatory / fibrotic diseases; and CBS004, a therapeutic mAb targeting BDCA-2 for the potential treatment of autoimmune diseases, as well as earlier-stage preclinical assets, including ORX750, an orally administered, selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and discovery-stage programs in certain other disease areas.
Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.
|IPO Date||May 28, 2021|
|CEO||Dr. Saurabh Saha M.D., Ph.D.|
3rd Floor, 1 Ashley Road
Altrincham, Cheshire, X0 WA14 2DT
|Phone||44 7391 789784|
|Fiscal Year||January - December|
|Dr. Saurabh Saha M.D., Ph.D.||Chief Executive Officer and Director|
|Dr. Gregory M. Weinhoff M.B.A., M.D., MBA||Principal Accounting Officer and Chief Financial Officer|
|Dr. Antoine Yver M.D., M.Sc., MSc||Executive Vice President and Chairman of Development|
|Dr. Thomas S. Templeman Ph.D.||Chief Technology Officer|
|Dr. David M. Chao Ph.D.||Chief Administrative Officer|
|Kristen K. Sheppard Esq., J.D.||Senior Vice President of Investor Relations and Corporate Communications|
|Iqbal J. Hussain L.L.B.||General Counsel, Chief Compliance Officer and Corporate Secretary|
|Karen M. Anderson||Chief People Officer|
|Tia L. Bush||Chief Quality Officer|
|Dr. David John Grainger Ph.D.||Chief Innovation Officer|
Latest SEC Filings
|Nov 13, 2023||10-Q||Quarterly Report|
|Nov 13, 2023||8-K||Current Report|
|Oct 25, 2023||8-K||Current Report|
|Sep 20, 2023||144||Filing|
|Sep 1, 2023||144||Filing|
|Aug 24, 2023||8-K||Current Report|
|Aug 14, 2023||10-Q||Quarterly Report|
|Aug 14, 2023||8-K||Current Report|
|Aug 1, 2023||144||Filing|
|Jul 10, 2023||8-K||Current Report|